Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-12-20
Target enrollment:
Participant gender:
Summary
The study is designed to demonstrate that axitinib plus best supportive care is superior to
placebo plus best supportive care in prolonging survival in patients with advanced
hepatocellular carcinoma.